Ani Pharmaceuticals (ANIP) said Wednesday it launched nitazoxanide tablets in 500 mg dosages, which are the generic version of the reference listed drug Alinia, indicated for the treatment of diarrhea.
The biopharmaceutical company said annual sales of nitazoxanide tablets in the US totaled $36.1 million in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.